重组改构人肿瘤坏死因子联合顺铂治疗肺癌恶性胸腔积液的效果

Abstract
Figure/Table
References (17)
Related Citation (15)

Download: PDF (0 KB) HTML (43 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the therapeutic effect and adverse reactions of recombinant mutant human tumor necrosis factor（rmh-TNF）combined cisplatin in the treatment of lung cancer with malignant pleural effusion. Methods Sixty patients of lung cancer with malignant pleural effusion from January 2013 to December 2014 in our hospital were chosen and randomly divided into treatment group and control group.Treatment group were injected intrapleurally with rmh-TNF combined cisplatin at a dose of 2×106U and 30 mg after complete drainage,once a week;control group were injected intrapleurally with cisplatin at a dose of 30 mg,once a week,the effect and adverse reactions were observed. Results Among the treatment group,14 patients were complete response（CR）,12 patients were partial response（PR）and 4 patients were no change（NC）,the overall response rate was 86.7％,among the control group,8 patients were CR,8 patients were PR and 14 patients were NC,the overall response rate was 53.3％,the difference was statistically significant （P＜0.01）.Common adverse reactions were common chest pain,the incidence of gastrointestinal reaction（malignant,vomiting）in treatment group was 43.3％（13/30）,23.3％（7/30）respectively, and was 33.3％（10/30）,30.0％（9/30）in control group,the difference was no statistically significant（P＞0.05）.The incidence of fever in treatment group was 46.7％（14/ 30）,and was 16.7％　（5/30）in control group,the difference was statistically significant（P＜0.05）. Conclusion The rmh-TNF combined cisplatin is effective in the treatment of lung cancer with malignant pleural effusion,and with slide adverse reactions.

Key words： Lung cancer Malignant effusion Recombinant mutant human tumor necrosis factor Cisplatin Injection intrapleurally

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HU Tao
	CHEN Xiao-lin
	HUANG Yu-min
	TAO Yu-jian

Cite this article:

HU Tao,CHEN Xiao-lin,HUANG Yu-min, et al. The therapeutic effect of rmh-TNF combined cisplatin in treating lung cancer with malignant pleural effusion[J]. 中国当代医药, 2016, 23(2): 47-49.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2016/V23/I2/47

[1]	谢灿茂.胸膜疾病的流行概况[J].中华结核和呼吸杂志，2001，24（1）：12-13．
[2]	Wu SG，Yu CJ，Tsai MF，et al.Survival of lung adenocarcinoma patients with malignant pleural effusion[J].Eur Respir J，2013，41（6）：1409-1428.
[3]	Postmus PE，Brambilla E，Chansky K，et al.The IASLC Lung Cancer Staging Project：proposals for revision of the M descriptors in the forth-coming（seventh）edition of the TNM classification of lung cancer[J].Thorac Oncol，2007，2 （8）：686-693.
[4]	周际昌.实用肿瘤内科学[M].2版.北京：人民卫生出版社，2010：102.
[5]	吴一龙.肺癌的多学科综合治疗的理论与实践[M].北京：人民卫生出版社，2000：280-283.
[6]	蒋剑.复方苦参注射液联合顺铂治疗恶性胸腔积液的临床效果[J].中国当代医药，2014，21（26）：113-115.
[7]	柳宝，张丽敏.鸦胆子乳油联合顺铂胸腔内灌注治疗肺癌所致恶性胸腔积液的疗效观察[J].中国当代医药，2012，19（7）：47-48.
[8]	刘飞，杭兆康，姜藻，等.香菇多糖联合顺铂与单药顺铂胸腔灌注治疗恶性胸腔积液的疗效对比研究[J].东南大学学报（医学版），2011，30（2）：367-369.
[9]	古翠萍，张沂平.TNF-α抗肿瘤作用机制新进展[J].中国肿瘤，2007，16（2）：102-105.
[10]	Frances B.Tumour necrosis factor and cancer[J].Nat Rev Cancer，2009，9（5）：361-371.
[11]	魏东，汤礼军，张伶，等.重组改构人肿瘤坏死因子治疗晚期肺癌癌性胸腔积液疗效的影响因素分析[J].重庆医科大学学报，2009，34（4）：472-475.
[12]	汪舸，闵海燕，张航.注射用重组改构人肿瘤坏死因子治疗恶性胸腔积液临床观察[J].现代肿瘤医学，2011，19（10）：2029-2030.
[13]	张小杰，秦艳茹，王峰，等.重组改构人肿瘤坏死因子治疗恶性胸腔积液疗效观察[J].中国实用医刊，2010，37 （10）：22-23.
[14]	李小云，王连祥.重组改构人肿瘤坏死因子治疗恶性胸腔积液180例疗效观察[J].山西医药杂志，2010，39（2）：142-143.
[15]	郑法德.胸腔穿刺置管引流联合顺铂腔内注射治疗恶性胸腔积液[J].临床肺科杂志，2012，17（1）：96-97.
[16]	刘澄英，倪华，邵荣，等.胸腔小导管联合顺铂腔内注射治疗恶性胸腔积液的临床研究[J].临床肺科杂志，2011，16（7）：1075-1076.
[17]	肖鑫武，李倩，宋勇，等.重组改构人肿瘤坏死因子对肺腺癌致恶性胸腔积液封胸治疗的临床疗效分析[J].医学研究生学报，2015，28（8）：836-839.